適応型COVID-19治療試験3（ACTT-3）

基本情報

NCT ID

NCT04492475

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

969

治験依頼者名

National Institute of Allergy and Infectious Diseases (NIAID)

概要

ACTT-3 will evaluate the combination of interferon beta-1a and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and oropharyngeal (OP) swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the subject to return to the clinic. In this case, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary outcome is time to recovery by Day 29.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)